Cumberland Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cumberland Pharmaceuticals Inc. on February 14, 2025. The report details a corporate action regarding the company's equity financing arrangements.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital market transaction.
Material Changes
On February 14, 2025, the Company increased the maximum aggregate offering price of its common stock issuable under the Sales Agreement with H.C. Wainwright & Co., LLC. The limit was raised to up to $10,000,000. A new prospectus supplement was filed to reflect this increase, amending the prior prospectus supplement dated March 20, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this report other than the standard legal opinion regarding the legality of the shares.
Key Facts for Investor Verification
- The maximum aggregate offering price under the At-the-Market (ATM) Sales Agreement with H.C. Wainwright & Co., LLC has been increased to $10,000,000.
- The transaction was executed via a new prospectus supplement filed on February 14, 2025.
- The Company's common stock trades on the NASDAQ Global Select Market under the symbol CPIX.
- No financial results or operational updates were included in this specific filing.